Is there benefit to give additional treatment beyond 4-6 cycles of first line therapy in advanced non-small cell lung cancer (85% of lung cancer in the US)? Watch the video below:
Recently, I met with a patient who was diagnosed with localized prostate cancer at a local urology office. He came to Swedish seeking a second opinion for the treatment of his prostate cancer. In doing this, he explained to me that after the diagnosis of his prostate cancer, he was referred to a website to review the available options for the management of prostate cancer and was given very little guidance by the urologist who made the diagnosis. Unfortunately, this is a common scenario in situations where the diagnosing urologist may not have all of the available treatment options at his or her disposal. In discussing this with him afterwards, he felt that the urologist was only interested in making a diagnosis but had no concern over his treatment choice and he felt very confused.
The patient and I sat down together in a 45 minute consultation visit to discuss his diagnosis. As I do with all of my patients recently diagnosed with prostate cancer, we covered the diagnosis, the available treatment options, and the relative risks of each so that he could make an informed decision. I feel fortunate to practice in a place that offers state-of-the-art therapy for prostate cancer by multiple modalities. At Swedish, we have ....